How Much Does Wegovy Cost? A Scenario-by-Scenario Guide

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This explainer lives in the PlexusDx Education Hub. Browse every Peptides & GLP-1 guide for the wider library.

"How much does Wegovy cost" has no single answer, because the number that lands at the pharmacy depends on your specific situation. This page takes a scenario-first approach: it starts from the published list price, then walks through what insured, partially-covered, and uninsured patients actually tend to face as of April 2026. The Education Hub holds the companion cost guides.

The list price as the anchor

Wegovy's list price is approximately $1,349 per month at U.S. list as of April 2026, per Novo Nordisk's published pricing. This is the starting point before insurance, rebates, manufacturer savings cards, and pharmacy negotiation act on it. It is rarely what most insured patients pay, but every scenario below is best understood as a discount, or lack of one, measured against this anchor figure.

Scenario one: covered and card-eligible

With commercial insurance that covers the indication and a manufacturer savings card applied, eligible patients may pay as little as $25 per month, subject to plan terms and caps. This is the most favorable common case. It requires that the plan's formulary and prior-authorization criteria are met and that the patient qualifies for the card, which generally excludes government-funded insurance.

Scenario two: insured but indication not covered

When commercial insurance does not cover the prescription's indication, the picture shifts. Cash cost typically lands closer to list price minus whatever coupon applies. Coverage for chronic weight management is more variable than for type 2 diabetes and is often gated behind BMI-based prior authorization, so patients in this middle zone frequently lean on independent coupons from platforms like GoodRx or SingleCare.

Scenario three: uninsured

Without insurance, cash cost approaches the list price, since most discounting levers are tied to coverage. Manufacturer savings cards generally require commercial insurance, leaving independent coupons and the compounded pathway as the main options. Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, which places some patients effectively in this uninsured-for-this-purpose position.

The compounded route across scenarios

Compounded semaglutide sits alongside all three scenarios as a separately priced option. During the FDA-declared shortages, licensed 503A compounding pharmacies legally produced compounded formulations; the FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025. These products are not identical to the brand and are priced through their own pathway, with PlexusDx publishing per-protocol pricing on each product page.

Genetics before the spend decision

Whichever scenario fits you, understanding your biology sharpens the decision. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, and MC4R that shape baseline appetite and energy balance. This is pathway education from 503A-aligned testing. It does not predict your response to any medication and is not pharmacogenomic; it is upstream context for the conversation, not a price.

What PlexusDx offers

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, and Tirzepatide Injection, each with pricing published on its product page. It does not sell or recommend other GLP-1 category peptides such as dulaglutide, liraglutide, retatrutide, or cagrilintide.

Finding your scenario first

The fastest way to a real number is to locate yourself among the three scenarios before comparing prices. Coverage status, the indication on the prescription, and savings-card eligibility do more to determine the final bill than the list price itself. Once you know which scenario fits, the relevant levers become obvious, and the wide range of prices quoted online resolves into the handful that actually apply to you. Because coverage rules and program terms shift over time, it is worth reconfirming your scenario whenever you refill rather than assuming last month's number still holds.

Frequently Asked Questions

What is the lowest a patient might pay?

In the most favorable common case, commercial insurance that covers the indication plus an applied manufacturer savings card can bring eligible patients to as little as $25 per month, subject to plan terms and caps. That outcome requires meeting the plan's formulary and prior-authorization criteria and qualifying for the card, which generally excludes government-funded insurance.

What do uninsured patients typically face?

Without insurance, cash cost approaches the roughly $1,349 monthly list price, because most discounts are tied to coverage. Independent coupons from platforms like GoodRx and SingleCare and the separately priced compounded pathway are the main levers left. Verifying current coupon terms at the time of fill is worthwhile, since they change frequently.

Does Medicare cover Wegovy?

Medicare does not cover FDA-approved weight-management drugs for weight alone as of April 2026, though cardiovascular-indication coverage exists for some products. That places some patients effectively in a cash-pay position for weight management. Checking directly with your plan is the reliable way to confirm what applies to your situation.

Can the genetic test change my cost scenario?

No. The Precision Peptide Genetic Test is not a pricing tool. It analyzes pathway-level variants such as FTO, and MC4R related to appetite and energy biology, offering context for a conversation with your provider. It does not predict response to any medication and is not pharmacogenomic.

This explainer lives in the PlexusDx Education Hub. Browse every Peptides & GLP-1 guide for the wider library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.